US EditionPublished • loading... • Updated
Eupraxia Pharmaceuticals Announces Positive Data From Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs - Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Eupraxia plans to double Phase 2b patient enrollment to at least 120 after 8 mg dose showed largest tissue health and eosinophil improvements in eosinophilic esophagitis trial.
Summary by Benzinga
9 Articles
9 Articles
Globe Newswire+6 Reposted by 6 other sources
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the...
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs - Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients in Cohort 9 experienced the largest improvements in tissue health outcomes and eosinophil reduction observed to date. RESOLVE Safety Committee and members of the Eupraxia Clinical Advisory Board endorsed using the 8 mg dose per injection as the secon…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources9
Leaning Left6Leaning Right1Center2Last UpdatedBias Distribution67% Left
Bias Distribution
- 67% of the sources lean Left
67% Left
L 67%
C 22%
11%
Factuality
To view factuality data please Upgrade to Premium
